CTT Pharmaceutical Holdings Discloses Change in Certifying Accountant via 8-K
CTT Pharmaceutical Holdings, Inc. (OTC-listed) filed an 8-K on October 7, 2026, disclosing a change in its certifying accountant (Item 4.01). Previously questioned over audit opinion type and internal control deficiencies, this move may signal preparation for a Nasdaq uplisting, requiring transition financial statements and new auditor due diligence within 90 days.
51CFO view：Accountant changes are high-risk for uplisting candidates: the CFO must manage audit workpaper transfers, restate prior-period financials (esp. revenue & R&D), and secure unqualified opinions covering ≥2 full fiscal years. This tests GAAP restatement expertise, SEC communication fluency, and audit project leadership.
CTT Pharmaceutical Holdings, Inc. (OTC-listed) filed an 8-K on October 7, 2026, disclosing a change in its certifying accountant (Item 4.01). Previously questioned over audit opinion type and internal control deficiencies, this move may signal preparation for a Nasdaq uplisting, requiring transition financial statements and new auditor due diligence within 90 days.
Source：SEC EDGAR · 8-K 重大事项公告